` 301080 (Acrobiosystems Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

301080
vs
S
Shanghai Composite

Over the past 12 months, Acrobiosystems Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +83% compared to the Shanghai Composite's +30% growth.

Stocks Performance
301080 vs Shanghai Composite

Loading
301080
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
301080 vs Shanghai Composite

Loading
301080
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
301080 vs Shanghai Composite

Loading
301080
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Acrobiosystems Co Ltd vs Peers

Shanghai Composite
301080
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Acrobiosystems Co Ltd
Glance View

Market Cap
9.9B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
56.8 CNY
Overvaluation 4%
Intrinsic Value
Price
Back to Top